Capital Advisors Ltd’s Acadia Pharmaceuticals ACAD Stock Holding History

Capital Advisors Ltd’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23	Closed	–	–	1307
2025 Q1	$0	Hold	23	–	–	﹤0.01%	1308
2024 Q4	$0	Buy	+23	New	+$371	﹤0.01%	1340

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Capital Advisors Ltd's ACAD Position: Q2 2025 in Review

Capital Advisors Ltd sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 23 shares.

Capital Advisors Ltd first reported a position in ACAD in Q4 2024 and held it in 2 quarters. The position peaked at $0 in Q1 2025. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

Capital Advisors Ltd reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Capital Advisors Ltd sold 23 Acadia Pharmaceuticals shares in Q2 2025.
Capital Advisors Ltd first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 2 quarters.
Capital Advisors Ltd's Acadia Pharmaceuticals position peaked at $0 in Q1 2025.
311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Capital Advisors Ltd's 13F filing for Q2 2025, filed 24 Jul 2025.